Bolt Biotherapeutics is a pioneering biotechnology company based in Redwood City, CA, dedicated to developing targeted immunotherapies that harness the power of the innate and adaptive immune systems to achieve long-term tumor remissions for cancer patients.
With a world-class team of fearless innovators, Bolt is at the forefront of a new category of immunotherapies that combine the precision of antibody targeting with the activation of the immune systems within the tumor microenvironment. Their pipeline includes promising candidates such as BDC-1001, a HER2 Boltbody ISAC currently in clinical development for the treatment of HER2 positive colorectal, endometrial, gastroesophageal, and metastatic breast cancer.
Generated from the website